acc01251 |
Histone H2B type 3-B |
oxidation |
Met63 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01252 |
U5 small nuclear ribonucleoprotein 200 kDa helicase |
oxidation |
Met229 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01253 |
Large ribosomal subunit protein P1 |
oxidation |
Met108 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01254 |
Large ribosomal subunit protein P2 |
oxidation |
Met109 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01255 |
Retinoblastoma-associated protein |
oxidation |
Met825 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01256 |
Nucleophosmin |
oxidation |
Met65 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01257 |
DNA topoisomerase 2-alpha |
oxidation |
Met1328 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01258 |
Nucleolin |
oxidation |
Met33 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01259 |
14-3-3 protein theta |
oxidation |
Met218 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01260 |
14-3-3 protein beta/alpha |
oxidation |
Met220 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01261 |
"14-3-3 protein beta/alpha, N-terminally processed" |
oxidation |
Met220 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01262 |
14-3-3 protein sigma |
oxidation |
Met223 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01263 |
14-3-3 protein gamma |
oxidation |
Met221 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01264 |
"14-3-3 protein gamma, N-terminally processed" |
oxidation |
Met223 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01265 |
14-3-3 protein epsilon |
oxidation |
Met218 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01266 |
General transcription factor IIF subunit 1 |
oxidation |
Met216 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01267 |
Microtubule-associated protein 1B |
oxidation |
Met1645 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01268 |
Microtubule-associated protein 1B |
oxidation |
Met830 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01269 |
Double-strand break repair protein MRE11 |
oxidation |
Met698 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01270 |
Microfibrillar-associated protein 1 |
oxidation |
Met127 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01271 |
"Actin, cytoplasmic 2" |
oxidation |
Met325 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01272 |
"Actin, cytoplasmic 2, N-terminally processed" |
oxidation |
Met325 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01273 |
"Actin, cytoplasmic 1" |
oxidation |
Met327 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01274 |
"Actin, cytoplasmic 1, N-terminally processed" |
oxidation |
Met327 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01275 |
"Actin, alpha skeletal muscle" |
oxidation |
Met326 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01276 |
"Actin, alpha skeletal muscle, intermediate form" |
oxidation |
Met327 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01277 |
Histone H4 |
oxidation |
Met85 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01278 |
Transformer-2 protein homolog beta |
oxidation |
Met208 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01279 |
"Actin, alpha skeletal muscle" |
oxidation |
Met84 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01280 |
"Actin, alpha skeletal muscle, intermediate form" |
oxidation |
Met84 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01281 |
"Actin, alpha cardiac muscle 1" |
oxidation |
Met83 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01282 |
"Actin, alpha cardiac muscle 1, intermediate form" |
oxidation |
Met84 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01283 |
CCAAT/enhancer-binding protein zeta |
oxidation |
Met644 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01284 |
TP53-binding protein 1 |
oxidation |
Met1107 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01285 |
Histone deacetylase 1 |
oxidation |
Met381 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01286 |
SNW domain-containing protein 1 |
oxidation |
Met230 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01287 |
Bystin |
oxidation |
Met93 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01288 |
Prostaglandin E synthase 3 |
oxidation |
Met126 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01289 |
Prostaglandin E synthase 3 |
oxidation |
Met127 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01290 |
Prostaglandin E synthase 3 |
oxidation |
Met130 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01291 |
Protein FAM133B |
oxidation |
Met147 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01292 |
ATP-dependent RNA helicase DDX42 |
oxidation |
Met164 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01293 |
Pre-mRNA-splicing factor 38A |
oxidation |
Met188 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01294 |
Protein LSM14 homolog A |
oxidation |
Met195 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01295 |
Histone deacetylase 2 |
oxidation |
Met373 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01296 |
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 |
oxidation |
Met106 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01297 |
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 |
oxidation |
Met108 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01298 |
Synembryn-A |
oxidation |
Met426 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Negative |
4.0 (Moderate) |
PXD000861
|
acc01299 |
WD repeat-containing protein 70 |
oxidation |
Met632 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|
acc01300 |
Serine/arginine repetitive matrix protein 2 |
oxidation |
Met1396 |
human |
Lung Cancer |
PC9IR |
Gefitinib |
Positive |
4.0 (Moderate) |
PXD000861
|